Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Structured reasoning failures compromise LLM interpretation of clinical oncology notes.

NPJ digital medicine·2026
Same author

Fine-Tuning, Retrieval-Augmented Generation, and Hybrid Large Language Models for Postoperative Decision Support: A Comparative Analysis.

Journal of medical Internet research·2026
Same author

Real-world use of lecanemab: patient pathway findings from a US multicenter study.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Federated target trial emulation for time-to-event outcomes via POLARIS: Pooled-equivalent One-shot Likelihood Aggregation for Real-world Inference in Survival.

Research square·2026
Same author

Optimizing Retrieval-Augmented Generation (RAG) in clinical medicine: methods and performance evaluation.

Journal of the American Medical Informatics Association : JAMIA·2026
Same author

From "negative" trial to positive clinical impact: mitigating eligibility criteria-induced temporal selection bias in emulated clinical trials.

npj health systems·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Sori Kim Lundin1,2, Yong Chen3, Paul E Schulz4

  • 1Center for Biomedical Semantics and Data Intelligence (CBSDI), University of Texas Health Science Center at Houston, Houston, TX, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 24, 2025
PubMed
概括
此摘要是机器生成的。

这项研究引入了一种新的AI模型,使用Kolmogorov-Arnold网络来预测轻度认知障碍患者的阿尔茨海默病风险. 该模型随着新数据的可用性而动态更新预测,提高了对现有方法的准确性.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 人工智能的人工智能
  • 神经科学是一个神经科学.
  • 生物统计学 生物统计学

背景情况:

  • 预测阿尔茨海默病 (AD) 风险对于精准医学和及时干预至关重要.
  • 早期识别从轻度认知障碍 (MCI) 发展为AD的个体是一个重大的临床挑战.

研究的目的:

  • 开发和评估基于人工智能的新型联合预测模型,用于MCI患者的纵向和生存数据.
  • 通过不断变化的患者数据,动态更新AD风险预测.

主要方法:

  • 一个基于科尔摩戈罗夫-阿诺德网络 (KANs) 的联合预测模型 (JM-KAN) 被开发出来.
  • 使用了来自国家阿尔茨海默氏症协调中心 (NACC) 对MCI患者数据集的真实数据.
  • 联合模型的构建与里程碑时间长达4年,预测生存结果一个年后的里程碑. 使用综合AUC (iAUC) 和综合布莱尔得分 (iBS) 来评估性能.

主要成果:

  • 该研究分析了2711名MCI患者,其中821人进展到AD.
  • JM-KAN模型实现了0.789的IAUC和0.118的IBS,在歧视和整体性能方面表现优于现有的联合模型.
  • 该模型在对纵向风险因素和生存概率的个性化预测方面取得了成功,因为每年出现新的数据.

结论:

  • 新的AI架构JM-KAN显著提高了AD风险的动态预测.
  • 这种方法改进了现有的方法,利用新的纵向数据不断更新风险评估.
  • 这些发现支持使用先进的AI模型来进行神经退行性疾病的动态风险分层.